Genmab A/S
General ticker "GNMSF" information:
- Sector: Health Care
- Industry: Biotechnology
- Capitalization: $14.5B (TTM average)
Genmab A/S follows the US Stock Market performance with the rate: 49.0%.
Estimated limits based on current volatility of 0.4%: low 289.67$, high 291.98$
Factors to consider:
- Total employees count: 548 as of 2019
Stock Forecast*
* forecast is subjective and experimental, should not be used for any investment decisions
Long term estimates were made for the period from 2025-12-31 to 2027-12-31
- 2025-12-31 to 2026-12-31 estimated range: [218.95$, 354.16$]
- 2026-12-31 to 2027-12-31 estimated range: [194.83$, 321.59$]
Short-term GNMSF quotes
Long-term GNMSF plot with estimates
Financial data
| YTD | 2025-12-31 |
|---|---|
| Operating Revenue | DKK24,544.66MM |
| Operating Expenses | DKK16,297.13MM |
| Operating Income | DKK8,247.53MM |
| Non-Operating Income | DKK-303.51MM |
| Interest Expense | DKK402.48MM |
| R&D Expense | DKK10,286.32MM |
| Income(Loss) | DKK7,944.02MM |
| Taxes | DKK1,590.12MM |
| Profit(Loss)* | DKK6,353.90MM |
| Stockholders Equity | DKK37,100.36MM |
| Inventory | DKK114.21MM |
| Assets | DKK81,681.70MM |
| Operating Cash Flow | DKK7,825.26MM |
| Capital expenditure | DKK244.13MM |
| Investing Cash Flow | DKK-37,232.66MM |
| Financing Cash Flow | DKK31,597.95MM |
| Earnings Per Share** | DKK102.23 |
* Profit(Loss) attributable to entity.
** EPS are Split Adjusted, recent splits may be reflected with a delay.